Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models

MLA

Kosuke Inoue, et al. “Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Prevents Local Recurrence after Insufficient Resection in Tongue Cancer Models.” Molecular Therapy: Oncolytics, vol. 30, no. 72–85, Sept. 2023, pp. 72–85. EBSCOhost, https://doi.org/10.1016/j.omto.2023.07.002.

APA

Kosuke Inoue, Hirotaka Ito, Miwako Iwai, Minoru Tanaka, Yoshiyuki Mori, & Tomoki Todo. (2023). Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models. Molecular Therapy: Oncolytics, 30(72–85), 72–85. https://doi.org/10.1016/j.omto.2023.07.002

Chicago

Kosuke Inoue, Hirotaka Ito, Miwako Iwai, Minoru Tanaka, Yoshiyuki Mori, and Tomoki Todo. 2023. “Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Prevents Local Recurrence after Insufficient Resection in Tongue Cancer Models.” Molecular Therapy: Oncolytics 30 (72–85): 72–85. doi:10.1016/j.omto.2023.07.002.